BRD4 and gastric neoplasm: Whether BRD4 loss resulted from PRDM1 knockdown rendering stomach cancer insensitive toward IBET151 was of concern, so further testing found shPRDM1-SNU-1 displayed decreased sensitivity toward IBET151 while this inhibitor showed an obvious suppression on shLuc-SNU-1 in terms of proliferation (Figure 4D).